pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2010-2-114-119pulmo-1638Research ArticleСтатьиЭффективность и безопасность раствора тобрамицина
для ингаляций в лечении синегнойной инфекции
при муковисцидозеБелоусовЮ. Б.noemail@neicon.ruЗыряновС. К.noemail@neicon.ruСоколовА. В.noemail@neicon.ruНациональное агентство клинической фармакологии и фармацииRussian Federation20102804201002114119Copyright © Белоусов Ю.Б., Зырянов С.К., Соколов А.В., 20102010Белоусов Ю.Б., Зырянов С.К., Соколов А.В.Белоусов Ю.Б., Зырянов С.К., Соколов А.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1638муковисцидозPseudomonas aeruginosaтобрамицинингаляциифармакокинетикаэффективностьбезопасностьReferencesCystic fibrosis foundation: About cystic fibrosis. www.cff.orgCystic fibrosis foundation: About cystic fibrosis. www.cff.orgCystic Fibrosis Fact Sheet 2006. www.lungusa.orgCystic Fibrosis Fact Sheet 2006. www.lungusa.orgAmerican Lung Association (ALA). Lung Disease Data: 2008. Available at: www.lungusa.org. Accessed on June 2008.American Lung Association (ALA). Lung Disease Data: 2008. Available at: www.lungusa.org. Accessed on June 2008.http://www.cf-rf.ru/content/ru/about_mucoviscidosis.html доступно: 03.2010.http://www.cf-rf.ru/content/ru/about_mucoviscidosis.html доступно: 03.2010.Davies J.C., Alton E.W., Bush A. Cystic fibrosis. Brit. Med. J. 2007; 335: 1255-1259.Davies J.C., Alton E.W., Bush A. Cystic fibrosis. Brit. Med. J. 2007; 335: 1255-1259.Flume P.A., S'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines. Chronic medication for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957-969.Flume P.A., S'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines. Chronic medication for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957-969.Dopfer R., Brand P., Mullinger B. et al. Inhalation of tobramycin in patient with cystic fibrosis: comparison of two methods. J. Physiol. Pharmacol. 2007; 58 (suppl. 5): 141-154.Dopfer R., Brand P., Mullinger B. et al. Inhalation of tobramycin in patient with cystic fibrosis: comparison of two methods. J. Physiol. Pharmacol. 2007; 58 (suppl. 5): 141-154.Maselli J.H., Sontag M.K., Norris J.M. et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr. Pulmonol. 2003; 35: 257-262Maselli J.H., Sontag M.K., Norris J.M. et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr. Pulmonol. 2003; 35: 257-262Gibson R.L., Emerson J., McNamara S. et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 841-849.Gibson R.L., Emerson J., McNamara S. et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 841-849.Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии: 3-е изд.; 2008.Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии: 3-е изд.; 2008.Moriarti T.F. et al. Intrapulmonary concentrations of tobramycin and ceftazidime archived after intravenous administration for the treatment of cistic fibrosis lung infections. J. Cyst. Fibros. 2006: 5 (suppl. 1); S20.Moriarti T.F. et al. Intrapulmonary concentrations of tobramycin and ceftazidime archived after intravenous administration for the treatment of cistic fibrosis lung infections. J. Cyst. Fibros. 2006: 5 (suppl. 1); S20.Гуревич К.Г., Белоусов Ю.Б. Клиническая фармакокинетика. М.: Литтерра; 2005.Гуревич К.Г., Белоусов Ю.Б. Клиническая фармакокинетика. М.: Литтерра; 2005.Bowman C.M. The longterm use of inhaled tobramycin in patients with cystic fibrosis. J. Cystic Fibrosis. 2002; 1: s194-s198Bowman C.M. The longterm use of inhaled tobramycin in patients with cystic fibrosis. J. Cystic Fibrosis. 2002; 1: s194-s198Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and P. aeruginosa infection. Pediatric. Pulmonol. 2002; 33: 269-276.Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and P. aeruginosa infection. Pediatric. Pulmonol. 2002; 33: 269-276.Ламберт П.А., Конвей Б.Р. Сравнение фармацевтического качества генерических препаратов цефтриаксона и роцефина. Клин. микробиол. антимикроб. химиотер. 2004; 6 (3): 260-272.Ламберт П.А., Конвей Б.Р. Сравнение фармацевтического качества генерических препаратов цефтриаксона и роцефина. Клин. микробиол. антимикроб. химиотер. 2004; 6 (3): 260-272.Wetterich U., Mutschler E., Rangoonwala R. Comparative quality assurance investigations of claforan and cefotaxime generics from India in respect to particulate matter. Proceedings of the 20th International Congress on Chemotherapy. Sydney, Australia, June 29July 3. 1997.Wetterich U., Mutschler E., Rangoonwala R. Comparative quality assurance investigations of claforan and cefotaxime generics from India in respect to particulate matter. Proceedings of the 20th International Congress on Chemotherapy. Sydney, Australia, June 29July 3. 1997.Lehr H.A., Brunner J., Rangoonwala R., Kirkpatrick C.J. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in post ischemic striated muscle. Am. J. Respir. Crit. Care Med. 2002; 165: 514-520.Lehr H.A., Brunner J., Rangoonwala R., Kirkpatrick C.J. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in post ischemic striated muscle. Am. J. Respir. Crit. Care Med. 2002; 165: 514-520.Nightingale C.H. A survey of the quality of generic clarithromycin product from 13 countries. Clin. Drug Invest. 2000; 19: 293-305.Nightingale C.H. A survey of the quality of generic clarithromycin product from 13 countries. Clin. Drug Invest. 2000; 19: 293-305.
The authors declare that there are no conflicts of interest present.